Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M, Tagliamento M, Bayle A, Vasseur D, Vergé V, Marinello A, Danlos FX, Blanc-Durand F, Bernard E, Cerbone L, Mosele MF, Renneville A, Hadoux J, Loriot Y, Sakkal M, Vozy A, Sarkozy C, Smolenschi C, Nicotra C, Martin-Romano P, Boccon-Gibod C, Habza W, Lazarovici J, Ponce S, Hollebecque A, Marzac C, Lacroix L, Barlesi F, André F, Besse B, Rouleau E, Italiano A, Micol JB. Aldea M, et al. Among authors: verge v. JCO Precis Oncol. 2023 Mar;7:e2200583. doi: 10.1200/PO.22.00583. JCO Precis Oncol. 2023. PMID: 36862966
Bone marrow metastases mimicking acute leukaemia.
Chraïbi S, Vergé V, Micol JB. Chraïbi S, et al. Among authors: verge v. Br J Haematol. 2019 Dec;187(5):556. doi: 10.1111/bjh.16224. Epub 2019 Oct 1. Br J Haematol. 2019. PMID: 31573071 Free article. No abstract available.
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, Vargaftig J, Uzunov M, Belhabri A, Bertoli S, Cotteret S, Vergé V, Renneville A, Rosselli F, Antony-Debre I, Rouleau E, Salviat F, Caron O, Delaloge S, Pautier P, Etienne G, Recher C, Vey N, De Botton S, Leary A, Marzac C, Micol JB. Martin JE, et al. Among authors: verge v. Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6. Ann Oncol. 2021. PMID: 34107346 Free article. No abstract available.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Sarkozy C, Michot JM, Quivoron C, Camara-Clayette V, Danu A, Lazarovici J, El-Dakdouki Y, Saleh K, Ghez D, Rossignol J, Baldini C, Arfi-Rouche J, Romano-Martin P, Tselikas L, Varga A, Gazzah A, Hollebecque A, Lacroix L, Bahleda R, Lecourt H, Vergé V, Rahali W, Cotteret S, Soria JC, Dartigues P, Massard C, Ribrag V. Sarkozy C, et al. Among authors: verge v. Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10. Am J Hematol. 2021. PMID: 34165816 Free article. Clinical Trial. No abstract available.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C. Quivoron C, et al. Among authors: verge v. Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. Haematologica. 2022. PMID: 35320922 Free PMC article. No abstract available.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: verge v. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: verge v. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E, Danu A, Ibrahim T, Lazarovici J, Ghez D, Michot JM, Arfi-Rouche J, Rossignol J, Vergé V, Dartigues P, Ribrag V. Rassy E, et al. Among authors: verge v. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e373-e380. doi: 10.1016/j.clml.2020.11.008. Epub 2020 Nov 13. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33277224
119 results